Davide Poli
Overview
Explore the profile of Davide Poli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiang X, Poli D, Degnan B, Degnan S
Mar Biotechnol (NY)
. 2022 Jul;
24(4):722-732.
PMID: 35895230
Investigations of host-symbiont interactions can benefit enormously from a complete and reliable holobiont gene expression profiling. The most efficient way to acquire holobiont transcriptomes is to perform RNA-Seq on both...
2.
Colombo N, Tomao F, Benedetti Panici P, Nicoletto M, Tognon G, Bologna A, et al.
Gynecol Oncol
. 2022 Jan;
164(3):505-513.
PMID: 35063281
Background: Previous findings showed that cediranib-olaparib increased PFS in women with recurrent platinum-sensitive ovarian cancer compared to olaparib alone. Methods: BAROCCO trial randomized 123 patients: 80mg/m2 paclitaxel weekly up to...
3.
Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F, et al.
Sci Rep
. 2020 Feb;
10(1):3189.
PMID: 32081876
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
4.
Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, et al.
Br J Cancer
. 2019 Sep;
121(9):744-750.
PMID: 31537908
Background: Trabectedin, in addition to its antiproliferative effect, can modify the tumour microenvironment and this could be synergistic with bevacizumab. The efficacy and safety of trabectedin and bevacizumab ± carboplatin...
5.
Quaranta L, Riva I, Biagioli E, Rulli E, Rulli E, Poli D, et al.
Adv Ther
. 2019 Jul;
36(9):2506-2514.
PMID: 31301054
Introduction: The CoQun study is a multicenter, controlled trial aimed to evaluate the neuroprotective effects of Coqun, an ophthalmic solution of Coenzyme q10 (CoQ10) and Vitamin E (VitE), in patients...
6.
Quaranta L, Biagioli E, Riva I, Galli F, Poli D, Rulli E, et al.
J Glaucoma
. 2018 Aug;
27(10):856-863.
PMID: 30095601
Purpose: To investigate the efficacy and safety of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery. Patients And Methods: Children with primary...
7.
Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F, et al.
Sci Rep
. 2018 Jan;
8(1):619.
PMID: 29330448
The aim of this study was to examine the relationship between visual field (VF) loss, vision-related quality of life (QoL) and glaucoma-related symptoms in a large cohort of primary open...
8.
Quaranta L, Biagioli E, Riva I, Galli F, Poli D, Rulli E, et al.
J Glaucoma
. 2017 Sep;
26(11):987-994.
PMID: 28957960
Purpose: To investigate the efficacy and safety of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery. Patients And Methods: Children with primary...
9.
Poli D, Fabbri E, Goffredo S, Airi V, Franzellitti S
PLoS One
. 2017 Feb;
12(2):e0171456.
PMID: 28199351
This study investigates for the first time the transcriptional regulation of a stress-inducible 70-kDa heat shock protein (hsp70) in the scleractinian coral Pocillopora verrucosa sampled at three locations and two...
10.
Quaranta L, Biagioli E, Galli F, Poli D, Rulli E, Riva I, et al.
Adv Ther
. 2016 Jun;
33(8):1305-15.
PMID: 27312975
Introduction: To investigate the efficacy of a treatment strategy with latanoprost and dorzolamide in primary pediatric glaucoma patients partially responsive to surgery. Methods: Single arm, prospective, interventional multicenter study. Primary...